Results 301 to 310 of about 703,542 (394)

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Real-World Utilization of Corticosteroids in Severe Alcoholic Hepatitis: Eligibility, Response, and Outcomes. [PDF]

Medicina (Kaunas)
Singeap AM, Minea H, Petrea O, Robea MA, Balmuș IM, Duta R, Ilie OD, Cimpoesu CD, Stanciu C, Trifan A.   +9 more
europepmc   +1 more source

Metabolic syndrome, non‐alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response [PDF]

, 2009
Zobair M. Younossi, Arthur J. McCullough
openalex   +1 more source

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

Small Methods, EarlyView.
The review presents a comprehensive overview of each component of lipid nanoparticles（LNPs）and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu, Nei Li, Yudian Xiao, Rohan Palanki, Hannah Yamagata, Michael J. Mitchell, Xuexiang Han   +6 more
wiley   +1 more source

Lipid Microparticle‐Based Phantoms Modeling Hepatic Steatosis for the Validation of Quantitative Imaging Techniques

Small Methods, EarlyView.
This paper presents a novel method for creating ultrasound phantoms that accurately replicate fat vesicle sizes encountered in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD). This approach can improve the understanding of liver fat measurement by creating ultrasound phantoms that link different quantitative imaging techniques to ...
Connor Endsley, Shariq Ali, Karim Salhadar, Adam Woodward, Shea Garland, Julien Santelli, Mehdi Zeighami Salimabad, Liqiang Ren, Takeshi Yokoo, Ivan M. Rosado‐Mendez, David T. Fetzer, Caroline de Gracia Lux   +11 more
wiley   +1 more source

A New Classification System for Fatty Liver—What Sonographers Should Know

Sonography, EarlyView.
ABSTRACT Hepatic steatosis or fatty liver disease is a rapidly emerging health issue and is closely linked to an increase in cardiometabolic conditions such as obesity and type 2 diabetes. The nomenclature surrounding fatty liver has recently undergone multiple reviews to better reflect its underlying causes.
Elspeth L. Keys, Katie L. McMahon, Elizabeth Powell, Heather Allen, Christopher Edwards   +4 more
wiley   +1 more source

Nanozymes in Reactive Oxygen Species‐Dependent Diseases: From Design and Preclinical Studies to Clinical Translation Prospects

Small Structures, EarlyView.
Nanozymes emerge as promising therapeutic agents for reactive oxygen species (ROS)‐dependent diseases, offering advantages over traditional biocatalysts through enhanced stability, tunability, and targeting capabilities. This review explores their mechanisms, design strategies, and clinical progress, emphasizing precision medicine potential.
Lihong Zhou, Jingyu Yan, Chenying Cui, Yurong Xu, Kaifang Zhang, Meijun Du, Zhuowei Zhang, Xiuping Wu, Bing Li   +8 more
wiley   +1 more source

Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims Hepatic encephalopathy is a frequent complication of cirrhosis. Rifaximin‐α has been included in guidelines for secondary prevention of hepatic encephalopathy, but there are few real‐world data on its efficacy and impact on healthcare utilization.
Diederick J. van Doorn, Kirsi. M. A. van Eekhout, Koos de Wit, L. C. Baak, Michael Klemt‐Kropp, Bart J. Verwer, Philip Friederich, Gijs J. de Bruin, Xander G. Vos, Joost P. H. Drenth, R. Bart Takkenberg   +10 more
wiley   +1 more source

Minimal Hepatic Encephalopathy in Cirrhotic Patients: A New Simple and Fast Digital Screening Method

United European Gastroenterology Journal, EarlyView.
ABSTRACT Backround Minimal hepatic encephalopathy is a common and prognostically severe complication of cirrhosis with a significant impact on the quality of life. Detailed diagnostic work‐up of minimal hepatic encephalopathy is time‐consuming and difficult to integrate into daily clinical routine.
Henrike Dobbermann, Raffael Schlüter, Yevgeniy Lyubchenko, Johanna Beder, Sven Danneberg, Katharina Mitzlaff, Iris Engelbart, Jakob Jessberger, Felix Braun, Thomas Becker, Christian Labenz, Monique Janneck, Denys Matthies, Friedhelm Sayk, Jens U. Marquardt   +14 more
wiley   +1 more source

Diagnosis and Monitoring Pathways Using Non‐Invasive Tests in Patients With Alpha‐1 Antitrypsin Deficiency‐Associated Liver Disease: Results From an Expert Delphi Panel

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims The severe alpha‐1 antitrypsin deficiency (AATD) genotype Pi*ZZ increases the risk of liver disease (AATD‐LD) and lung disease. While non‐invasive tests (NITs) are widely used for fibrosis stage and monitoring of all liver diseases, the consensus for use in AATD‐LD is limited.
Virginia C. Clark, Mark A. Price, Jon Russo, Rohit Loomba, Alice M. Turner, Pavel Strnad   +5 more
wiley   +1 more source